Taiwania Capital
Kevin Chih-Yuan Ho is currently an Investment Manager at Taiwania Capital. Prior to this, Kevin Chih-Yuan held the position of Director of Business and Clinical Development at Steminent Biotherapeutics Inc., a global biopharmaceutical company. Kevin Chih-Yuan has also served as the President of the National Taiwan University Alumni UK Association and gained experience as an Internship Trainee at SinoPac Securities. With a background in Biomedical Engineering, Kevin's expertise spans various industries including project consultancy in the construction sector and research assistance in a hospital setting.
This person is not in any offices
Taiwania Capital
1 followers
Taiwania Capital is a venture capital firm founded in August 2017 by the National Development Fund of the Executive Yuan of Taiwan and private enterprises. Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth. Taiwania Capital is a venture capital that focuses on investing in technologies and biotech areas start-ups that are Taiwan or US-based with disruptive and advanced technology. Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.